Alnylam Pharmaceuticals (ALNY) EBITDA: 2009-2025
Historic EBITDA for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Sep 2025 value amounting to $259.3 million.
- Alnylam Pharmaceuticals' EBITDA rose 354.78% to $259.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.6 million, marking a year-over-year increase of 114.35%. This contributed to the annual value of -$289.3 million for FY2024, which is 30.95% up from last year.
- Per Alnylam Pharmaceuticals' latest filing, its EBITDA stood at $259.3 million for Q3 2025, which was up 541.58% from -$58.7 million recorded in Q2 2025.
- Alnylam Pharmaceuticals' EBITDA's 5-year high stood at $259.3 million during Q3 2025, with a 5-year trough of -$407.5 million in Q3 2022.
- In the last 3 years, Alnylam Pharmaceuticals' EBITDA had a median value of -$69.5 million in 2024 and averaged -$51.7 million.
- Its EBITDA has fluctuated over the past 5 years, first plummeted by 166.73% in 2024, then soared by 354.78% in 2025.
- Over the past 5 years, Alnylam Pharmaceuticals' EBITDA (Quarterly) stood at -$257.5 million in 2021, then rose by 19.08% to -$208.4 million in 2022, then soared by 38.13% to -$128.9 million in 2023, then climbed by 27.50% to -$93.5 million in 2024, then surged by 354.78% to $259.3 million in 2025.
- Its EBITDA was $259.3 million in Q3 2025, compared to -$58.7 million in Q2 2025 and -$60.5 million in Q1 2025.